Pro-Dynabol 20mg (Methandienone) 50 Tablets

Pro-Dynabol 20mg (Methandienone) 50 Tablets | iRoids Pharma

Pro-Dynabol 20mg is an oral anabolic steroid containing 20mg of Methandienone per tablet, available in packs of 50 tablets. At iRoids Pharma, we carry Pro-Dynabol 20mg as part of our oral anabolic steroid inventory for customers in markets where Methandienone is legally available.

Methandienone is the active compound in this preparation. Pro-Dynabol is the brand designation under which this specific Methandienone preparation is marketed at iRoids Pharma. The compound is also widely recognized under the brand names Dianabol and Dbol, and referenced in pharmacological literature as Methandrostenolone. All three names describe the same active pharmacological entity. Pro-Dynabol consequently contains the same active compound whose pharmacological profile, clinical background, and health considerations are referenced throughout the extensive Methandienone research literature under these designations.

The 20mg tablet format represents a mid-range concentration within the Methandienone product landscape, sitting between the conservative 10mg format and the highest-concentration 50mg format. This page covers the pharmacology, brand-specific context, concentration-specific considerations, and health and legal context relevant to anyone researching Pro-Dynabol at iRoids Pharma. It does not constitute medical advice, recommend steroid use, or provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

About the Pro-Dynabol Brand

Pro-Dynabol is a non-prescription Methandienone preparation marketed under a distinct brand identity within the iRoids Pharma product catalog. The Pro-Dynabol brand designation identifies this specific preparation as distinct from other Methandienone products available in the non-prescription market while containing the same active Methandienone compound at the same pharmacological activity level as any other 20mg Methandienone preparation.

The Pro-Dynabol brand name follows the naming convention used across several compounds in the non-prescription performance market where brand identifiers distinguish manufacturer-specific preparations containing the same active pharmaceutical ingredients as other market preparations of the same compound. Buyers researching Pro-Dynabol will consequently find the pharmacological literature for this compound referenced under the Methandienone generic name, the Methandrostenolone CIBA designation, and the Dianabol brand name rather than under the Pro-Dynabol brand designation specifically.

The pharmacological profile described throughout this page applies to Methandienone as an active compound regardless of the specific brand designation under which it is marketed. Pro-Dynabol at iRoids Pharma consequently carries the same pharmacological mechanisms, clinical reference background, and health and legal considerations as any other 20mg Methandienone preparation.

Nomenclature: Pro-Dynabol, Methandienone, Methandrostenolone, and Dianabol

The naming landscape for this compound requires direct clarification because buyers researching Pro-Dynabol will encounter multiple designations across different sources.

Methandienone is the International Nonproprietary Name and the designation used in British Pharmacopoeia and several European regulatory frameworks. Methandrostenolone was the name under which CIBA originally developed and marketed the compound. Dianabol is the brand name under which it reached commercial markets globally and remains the most universally recognized non-generic designation. Pro-Dynabol is the specific brand name under which iRoids Pharma markets this particular Methandienone preparation.

All four names consequently refer to the identical pharmacological entity. The research literature uses Methandienone and Methandrostenolone interchangeably across different publication contexts. Understanding this nomenclature landscape is relevant for anyone researching the pharmacological and safety literature for this compound across different sources.

What Is Methandienone

Methandienone is a synthetic anabolic-androgenic steroid derived from testosterone. CIBA Pharmaceuticals developed it in 1955 under the direction of Dr. John Ziegler, who introduced it to American competitive athletics through his work with the United States weightlifting team in the late 1950s. The compound reached the US market under the Dianabol brand name in 1958. Within a decade it had achieved the status of the most widely used oral anabolic steroid globally, a distinction it has maintained in non-prescription markets despite FDA market withdrawal in 1985.

Structurally, Methandienone carries two modifications from the testosterone molecule. A methyl group at the 17-alpha carbon position enables oral bioavailability by protecting the compound from hepatic first-pass metabolism. A double bond at the carbon-1 and carbon-2 positions of the steroid A-ring reduces androgenic receptor affinity in non-target tissues while preserving strong anabolic receptor activation in muscle tissue. These modifications produce an anabolic rating of 90 to 210 and an androgenic rating of 40 to 60 relative to a testosterone baseline of 100. The compound aromatizes significantly to estradiol through the aromatase enzyme pathway, which is the mechanistic basis for the most commonly reported immediate side effects of Methandienone use.

How Methandienone Works

Methandienone reaches systemic circulation in active form following oral administration due to the hepatic protection provided by 17-alpha alkylation. It subsequently interacts with multiple biological systems through several distinct pharmacological mechanisms.

Androgen Receptor Activation

Methandienone binds to androgen receptors in skeletal muscle and activates receptor-mediated gene transcription programs that regulate protein synthesis and nitrogen retention. The double bond modification reduces its affinity for androgen receptors in non-target tissues relative to unmodified testosterone. As a result, the primary anabolic effects are produced in muscle tissue with comparatively less androgenic activation in tissues associated with androgenic side effects. At the 20mg concentration, androgen receptor activation is twice as pronounced per tablet as at the 10mg format.

Nitrogen Balance

Methandienone produces strongly positive nitrogen balance in skeletal muscle tissue. The body retains substantially more nitrogen than it excretes, supporting a pronounced anabolic environment where protein accumulation dominates over protein breakdown. This mechanism is among the most consistently documented pharmacological effects of Methandienone across both clinical literature and decades of observational data.

Glycogenolysis

Methandienone enhances glycogenolytic activity in muscle tissue, improving the efficiency of glycogen breakdown and glucose availability during high-intensity muscular activity. This metabolic mechanism adds a dimension to Methandienone’s pharmacological profile beyond its direct androgen receptor-mediated anabolic effects. Consequently, this contributes to the strength and acute performance observations associated with this compound in addition to its longer-term effects on muscle protein accretion.

Aromatase-Mediated Estrogen Conversion

Methandienone undergoes significant conversion to estradiol through aromatase in peripheral tissues. This estrogenic conversion produces systemic estrogen elevation driving extracellular fluid retention, breast glandular tissue stimulation, and mood-related hormonal effects. At the 20mg concentration, estrogenic conversion is twice as pronounced per tablet as at the 10mg format. Estrogen management is consequently a more prominent consideration at the 20mg concentration than at the more conservative 10mg format.

IGF-1 Production

Methandienone stimulates Insulin-like Growth Factor 1 production through androgen receptor-mediated mechanisms. IGF-1 functions as a downstream anabolic mediator in muscle tissue, activating satellite cells and stimulating protein synthesis. This secondary anabolic pathway amplifies the direct androgen receptor-mediated effects and is proportionally more active at the 20mg concentration than at the 10mg format.

The 20mg Concentration Within the Pro-Dynabol Context

Position Within the iRoids Pharma Methandienone Range

The 20mg format of Pro-Dynabol occupies a specific position within the iRoids Pharma Methandienone product range. It delivers double the active compound per tablet compared to the 10mg Methandienone format and 40 percent of the active compound per tablet compared to the 50mg format. Every dose-dependent pharmacological effect and side effect is consequently twice as pronounced per tablet as at the 10mg format and proportionally less pronounced than at the 50mg format. Pro-Dynabol 20mg consequently occupies a practical middle ground between the most conservative and most potent Methandienone formats in the iRoids Pharma catalog.

Historical Pharmaceutical Reference

Pharmaceutical grade Dianabol was historically produced at 2.5mg and 5mg tablet formats in the United States and at 5mg and 10mg formats in several international markets. The 20mg concentration doubles the upper end of the historical pharmaceutical clinical tablet format. The primary clinical research base for Methandienone, accumulated during its period of pharmaceutical availability from 1958 through 1985, was established at doses consistent with the 5mg and 10mg historical formats. As a result, the 20mg concentration of Pro-Dynabol falls outside the concentration range most directly characterized by the controlled clinical literature.

50 Tablet Pack Context

Each Pro-Dynabol pack contains 50 tablets at 20mg per tablet, providing a total of 1000mg of active Methandienone per pack. This represents double the total active compound per pack compared to a 50-tablet pack at the 10mg concentration. The higher total active compound per pack consequently amplifies the cumulative hepatotoxicity and cardiovascular lipid considerations relative to a lower-concentration equivalent pack size.

Clinical Background

Methandienone carries an extensively documented clinical history accumulated during its period of pharmaceutical market availability from 1958 through 1985.

Original Clinical Development

CIBA developed Methandienone with specific clinical applications in mind including treatment of hypogonadism, osteoporosis, and conditions associated with accelerated protein catabolism. The FDA approved it for these indications and it remained commercially available in the United States until 1985 when CIBA discontinued marketing following regulatory pressure.

Research Literature From the Pharmaceutical Era

The clinical and research literature from the 1958 to 1985 period covers Methandienone’s effects on nitrogen balance, protein synthesis, bone density, red blood cell production, and multiple organ systems. This research base was accumulated primarily at doses consistent with the 5mg and 10mg historical pharmaceutical formats. The 20mg concentration of Pro-Dynabol consequently falls outside the concentration range most directly characterized by this controlled clinical literature.

Post-Market Withdrawal Context

Following FDA market withdrawal in 1985, controlled clinical research became limited. The research base is supplemented by extensive observational data from non-prescription market use across multiple decades. This observational data provides pharmacological context that extends beyond the controlled research literature, particularly for higher concentration formats that exceed historical pharmaceutical dosing.

Pro-Dynabol Versus Other Compounds at iRoids Pharma

Versus Methandienone 10mg and 50mg at iRoids Pharma

All three formats contain the same active Methandienone compound with identical pharmacological mechanisms. Pro-Dynabol 20mg delivers double the active compound per tablet compared to the 10mg format and 40 percent of the active compound per tablet compared to the 50mg format. Every dose-dependent pharmacological effect and side effect is consequently twice as pronounced per tablet as at the 10mg format and proportionally less pronounced than at the 50mg format.

Versus Superdrol 10mg

Superdrol 10mg contains Methasterone, a non-aromatizing DHT derivative with an anabolic rating of 400 and severe hepatotoxicity. Pro-Dynabol 20mg contains Methandienone, a testosterone derivative that aromatizes significantly with an anabolic rating of 90 to 210 and significant but comparatively less severe hepatotoxicity. These two compounds carry fundamentally different estrogenic profiles. Pro-Dynabol produces significant estrogenic conversion. Superdrol produces none. Superdrol consequently carries a dry profile while Pro-Dynabol produces the estrogenic water retention and gynecomastia risk associated with significant aromatization.

Versus Winstrol 10mg

Winstrol 10mg contains Stanozolol, a non-aromatizing DHT derivative with significant hepatotoxicity and adverse lipid effects. Pro-Dynabol 20mg aromatizes significantly to estrogen and carries significant hepatotoxicity. Both are 17-alpha alkylated oral anabolic steroids. However, Stanozolol’s non-aromatizing profile produces a fundamentally different estrogenic side effect consideration than Methandienone. Additionally, Stanozolol produces the collagen synthesis reduction and joint discomfort that Methandienone does not specifically generate through the same mechanism.

Versus Anastrozole 1mg

Anastrozole 1mg is a dedicated aromatase inhibitor producing approximately 70 to 80 percent estrogen suppression with no androgenic activity. Pro-Dynabol 20mg is a potent oral anabolic steroid that aromatizes significantly to estrogen. In performance community discussions, Anastrozole is commonly referenced in relation to Methandienone use specifically because of Methandienone’s pronounced aromatization. These two compounds consequently serve entirely different pharmacological roles within the iRoids Pharma catalog while being frequently discussed in the same context due to the estrogen management considerations associated with aromatizing anabolic steroid use.

Versus Mesterolone 25mg

Mesterolone 25mg is a non-17-alpha alkylated oral androgen with low hepatotoxicity, mild aromatase inhibition, SHBG binding, and minimal HPG suppression. Pro-Dynabol 20mg is a 17-alpha alkylated oral anabolic steroid with significant hepatotoxicity, strong aromatization to estrogen, and meaningful HPG suppression. These two compounds represent fundamentally opposite pharmacological profiles across virtually every relevant parameter and serve different primary pharmacological roles within the iRoids Pharma catalog.

Side Effects and Health Risks

Pro-Dynabol 20mg carries a well-documented side effect profile based on the extensive Methandienone clinical and observational literature. The 20mg concentration makes every dose-dependent consideration twice as pronounced per tablet as at the 10mg format. These risks are real and require responsible attention regardless of the brand designation under which the compound is marketed.

Hepatotoxicity

Hepatotoxicity is the most clinically significant health risk associated with Methandienone use at any concentration. The 17-alpha alkylation places direct metabolic stress on hepatocytes. At the 20mg concentration, hepatic stress is twice as pronounced per tablet as at the 10mg format. Elevated liver transaminase values, cholestatic effects, and in cases of prolonged use more serious structural hepatic complications are documented in the clinical literature. Biochemical liver function monitoring is consequently essential for anyone using Pro-Dynabol at any concentration.

Estrogenic Effects

Aromatase-mediated conversion to estradiol produces the most commonly reported immediate side effects of Methandienone use. Extracellular fluid retention, breast glandular tissue stimulation, and mood-related hormonal effects are all downstream consequences of estrogen elevation. At the 20mg concentration these estrogenic effects are twice as pronounced per tablet as at the 10mg format. Aromatase inhibitor co-administration is frequently referenced in performance community discussions as an estrogen management approach with Methandienone use at any concentration.

Cardiovascular Effects

Methandienone produces adverse lipid profile modifications including HDL suppression and LDL elevation documented consistently across the clinical literature. Water retention from estrogenic conversion additionally produces blood pressure elevation through increased circulating volume. At the 20mg concentration these cardiovascular considerations are twice as pronounced per tablet as at the 10mg format. Active cardiovascular monitoring is consequently essential for anyone using Pro-Dynabol.

HPG Axis Suppression

Methandienone suppresses the hypothalamic-pituitary-gonadal axis through negative feedback on gonadotropin-releasing hormone secretion, reducing endogenous testosterone production during use. At the 20mg concentration HPG suppression is twice as pronounced per tablet as at the 10mg format. Post-use HPG recovery varies in duration and completeness and in some cases requires medical intervention.

Androgenic Effects

Despite its comparatively reduced androgenic rating, Methandienone still produces androgenic side effects in susceptible individuals. Accelerated androgenetic alopecia and acne are the most consistently reported androgenic effects. In women, virilization represents serious and potentially irreversible consequences at any concentration of this compound.

Psychological Effects

Anabolic steroid use carries documented associations with mood changes and irritability. These effects are proportionally more pronounced at the 20mg concentration than at the 10mg format and remain relevant health considerations for anyone using Pro-Dynabol over extended periods.

Legal and Regulatory Status

Methandienone carries Schedule III controlled substance status in the United States under the Anabolic Steroid Control Act. The FDA withdrew its market approval in 1985. Possession without a valid prescription consequently constitutes a federal offense.

In the United Kingdom, Methandienone is classified as a Class C controlled substance under the Misuse of Drugs Act. Unauthorized supply is a criminal offense.

The World Anti-Doping Agency includes Methandienone on its prohibited list across all competitive sport categories. Urinary detection of Methandienone metabolites is possible for extended periods following cessation of use.

You are responsible for confirming the legal status of Methandienone in your specific jurisdiction before purchasing from iRoids Pharma.

Frequently Asked Questions

Is Pro-Dynabol 20mg Available at iRoids Pharma

Yes. iRoids Pharma carries Pro-Dynabol 20mg in packs of 50 tablets for customers in markets where Methandienone is legally available. Visit iroidspharma.com to check current availability and pricing.

What Is the Difference Between Pro-Dynabol and Generic Methandienone

Both preparations contain Methandienone as the sole active compound at identical concentrations. The distinction is the specific manufacturer and brand identity of the preparation rather than any pharmacological difference in the active compound. The pharmacological profile, mechanisms of action, clinical reference background, and side effect considerations are identical.

What Is Pro-Dynabol, Dianabol, Methandienone, and Methandrostenolone

All four names refer to the same active pharmacological compound. Pro-Dynabol is the specific brand name used at iRoids Pharma. Dianabol is the most universally recognized commercial brand name. Methandienone is the International Nonproprietary Name. Methandrostenolone was the original CIBA designation. The pharmacological literature consequently references this compound under all four names across different publication and market contexts.

What Is the Half-Life of Methandienone

Methandienone produces a half-life of approximately 3 to 6 hours. This relatively short half-life requires regular daily administration to maintain stable plasma concentrations throughout the day. This pharmacokinetic characteristic applies equally across all Methandienone concentration formats including Pro-Dynabol 20mg.

How Many Tablets Are in Each Pro-Dynabol Pack

Each iRoids Pharma Pro-Dynabol pack contains 50 tablets at 20mg per tablet, providing a total of 1000mg of active Methandienone per pack.

Does Methandienone Aromatize

Yes. Methandienone undergoes significant aromatase-mediated conversion to estradiol. Estrogenic side effects including fluid retention and breast tissue stimulation are consequently primary health considerations at any Methandienone concentration including the 20mg Pro-Dynabol format.

How Does Pro-Dynabol 20mg Compare to the 10mg Format

Both formats contain the same active Methandienone compound with identical pharmacological mechanisms. Pro-Dynabol 20mg delivers double the active compound per tablet compared to the 10mg format. Every dose-dependent pharmacological effect and side effect is consequently twice as pronounced per tablet at the 20mg concentration. The 10mg format provides greater dose precision and more conservative per-tablet exposure. Pro-Dynabol 20mg provides more potent per-tablet activity for anyone researching higher daily exposure levels.

What Are the Most Serious Health Risks

Hepatotoxicity from 17-alpha alkylation is the most clinically significant health risk and is twice as pronounced per tablet as at the 10mg format. Cardiovascular effects from lipid modification and fluid retention, estrogenic effects from significant aromatization, and HPG suppression complete the primary risk profile. Medical supervision and regular biochemical monitoring are consequently essential for anyone using Pro-Dynabol at any concentration.

Is Pro-Dynabol 20mg Legal to Purchase

Methandienone carries Schedule III controlled substance status in the United States. Legal status varies significantly by jurisdiction. You are consequently responsible for confirming the legal status in your jurisdiction before purchasing from iRoids Pharma.

What to Consider Before Purchasing Pro-Dynabol 20mg

Methandienone carries one of the most extensively documented pharmacological profiles of any oral anabolic steroid ever produced. The research and clinical observation base accumulated during its period of pharmaceutical availability from 1958 through 1985 provides a meaningful pharmacological reference context that applies to the active compound regardless of the specific brand designation or manufacturer. Pro-Dynabol is the brand designation under which iRoids Pharma markets this preparation. The pharmacological and risk profile is identical to any other 20mg Methandienone preparation.

The 20mg format of Pro-Dynabol delivers double the per-tablet active compound compared to the 10mg format while providing significantly greater dose precision than the 50mg format. It occupies a specific practical middle ground between the most conservative and most potent Methandienone formats in the iRoids Pharma catalog. The clinical research base established at historical pharmaceutical doses of 5mg to 10mg does not directly characterize the side effect profile at 20mg per tablet, making the observational data from non-prescription market use a more relevant reference at this concentration.

The iRoids Pharma non-prescription preparation does not carry the manufacturing oversight of pharmaceutical grade Dianabol. The clinical research base applies to the pharmacological and risk profile of the active compound regardless of the specific manufacturer or brand designation. Manufacturing standards and quality verification consequently differ between pharmaceutical grade and non-prescription preparations.

Methandienone carries documented hepatotoxicity, cardiovascular, estrogenic, HPG suppression, androgenic, and psychological health risks. All dose-dependent considerations are twice as pronounced per tablet at the 20mg concentration as at the 10mg format. Medical supervision and regular biochemical monitoring are consequently essential for anyone using Pro-Dynabol at any concentration.

For customers in markets where Methandienone is legally available, visit iroidspharma.com to check current Pro-Dynabol 20mg availability, pricing, and stock levels.